Deadline: 21-Sep-21
The European Commission (EC) is seeking proposals for the Development, procurement and responsible management of new antimicrobials to prepare for the establishment of a pull incentive for new antimicrobials where there is an unmet public health need and a market failure.
In line with the Pharmaceutical Strategy for Europe that was published in November 2020 innovative approaches at EU level should be developed for supporting research, development and public procurement of antimicrobials to address the issue of antimicrobial resistance.
These approaches could make use of European legislation, such as the possibility of an innovation partnership that would allow for the combination of development of new antimicrobials and procurement elements and should be tailored to public health needs.
Proposals are expected to address all of the following:
- Emerging health threats, particularly those resulting from antimicrobial resistance (AMR), and identification of relevant public health needs in the development of new antibiotics.
- Design of a feasible option for a pull incentive that combines EU support for late stage development of antimicrobials with procurement by Member States and Associated Countries (implementation of the pull incentive will be beyond the scope of this CSA).
- Readiness and interest of potential developers/suppliers of antimicrobials
- Market failures and the challenges of availability and accessibility of therapeutics.
- Conditions for development and purchase of new antimicrobials.
- Requirements for financing.
- Conditions for prudent use of new antimicrobials.
Funding Information
The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:
- public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
- cases where the individual requested grant amount is not more than EUR 60 000 (lowvalue grant).
Expected Outcomes
To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:
- Health authorities and healthcare providers have identified the needs and potential procurers;
- Potential procurers are ready to establishing an innovation partnership for the development and the procurement of new antimicrobials;
- Potential procurers are able to engage and commit financially in view of the establishment of an innovation partnership.
Eligibility Criteria
To be eligible for funding, applicants must be established in one of the eligible countries, i.e.:
- the Member States of the European Union, including their outermost regions;
- the Overseas Countries and Territories (OCTs) linked to the Member States;
- eligible non-EU countries:
- countries associated to Horizon Europe;
- low- and middle-income countries.
For more information, visit https://bit.ly/3xkrAwf
